about
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeysBehavioural profiles in captive-bred cynomolgus macaques: towards monkey models of mental disorders?Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the grooveDifferential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in ratsPSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor traffickingNeuroanatomical study of the A11 diencephalospinal pathway in the non-human primateStriatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.Spatiotemporal neuromodulation therapies engaging muscle synergies improve motor control after spinal cord injury.Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGEStriatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure.A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.D1 dopamine receptor-mediated LTP at GABA synapses encodes motivation to self-administer cocaine in rats.Double-dissociation of the catecholaminergic modulation of synaptic transmission in the oval bed nucleus of the stria terminalis.Migration and differentiation of human mesenchymal stem cells in the normal rat brain.Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapySystemic gene delivery to the central nervous system using Adeno-associated virus.Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesiaFrom experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research?Misrepresentation of neuroscience data might give rise to misleading conclusions in the media: the case of attention deficit hyperactivity disorder.Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death.Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia.Astrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology?Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.Direct targeted quantitative molecular imaging of neurotransmitters in brain tissue sections.Prototypic and arkypallidal neurons in the dopamine-intact external globus pallidus.Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease.Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques.Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.Modeling Parkinson's disease in primates: The MPTP modelNanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases.Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration.
P50
Q27316473-78867D21-8C91-442D-99B4-D99BA285507BQ27323164-252DAB14-112D-4BEF-B36C-3D112B89B21BQ27324174-D02EF110-DB9D-4918-B20F-C0C3BC38B30BQ28115428-D33ADD22-343C-4DE4-B16C-4DE3DF897E0DQ28278798-3681E586-7AAA-401D-B1DF-C24D1B5C8872Q28582674-49A036D7-13C1-46C7-987F-7ED3B32DC9DBQ28748883-8F03D768-E157-47C5-B25D-54EB040CDCFEQ30493275-80EBC948-A35A-4A7C-B1D3-3BE2605FF593Q30658867-30FC5D8E-2E0B-4B1D-AABA-780B57A0BFA6Q30821299-A7BF2E2D-D6DF-415E-A49C-37DC1844B625Q30988635-35CC3B66-B3B0-4E79-A0A3-E25DA0F8FE0DQ33261647-6CA90BC0-78EA-4A2C-8CAC-76DCCC860CD5Q33319566-2FED11A7-FFB8-4914-8208-6DEAC739AABCQ33572574-42663504-8702-4BD1-B243-BD672358E162Q33573158-C88E3D87-47D8-4FA0-A3CD-C8A1C0A8958EQ33573249-ED594DDF-EEAF-49EA-A9BE-F6946CE7E4F7Q33582855-9AD717AD-919F-48C9-ABF7-47480BE3BDF3Q33603197-6BA8B8B3-4B09-49E7-AF4F-56FD99E74A18Q33695674-179C6C98-96CC-4E74-ABD8-471A654F3B09Q33725654-A0B84F37-CC13-4042-95B8-371F1FACA4A9Q33749068-16C55993-26E8-4660-9DFE-B8591E756C0CQ33812910-2DAEACBB-F415-44F1-8484-5743CA59CF46Q33835745-48FCAA93-31FE-4F4D-AC75-C5252339B51CQ33992550-CB00E488-DBA7-44FB-9DB9-597AD467F987Q34043163-7E16F965-43D7-40E6-BEDF-367C9F4DE710Q34165820-7710CEEE-DCF4-4F98-86FE-E40884779315Q34238909-C26FBF16-3781-4B6E-A911-AB0B929849C2Q34330176-D450BF59-9E9F-47C9-BE62-8B5ADEEA7693Q35012627-7744BDC1-4328-40AB-A4A5-8519A9905329Q35195868-9D2F00F5-3376-4A0B-8D2D-8F3202377EF0Q35469733-534CDE09-3F5A-4C49-837E-6430E65E8091Q35547863-E3084829-0976-4282-9707-FCF8E70A2B36Q35586627-220C4FCE-1A5A-4723-9DD5-20685AEE2486Q35622290-F8CB883C-F965-4614-B4D4-B33FD91656EFQ35713145-B06503B4-7F40-42A8-B2A7-0D5093A90151Q35746222-0624E9A2-EF30-4541-851E-7E8DFC9B7028Q35761616-7C830411-8286-49E5-A0AD-4D68A972DB35Q35765748-2E85CF17-86CE-4AE9-A12D-6F10A6FE9B41Q35892854-4F29B570-0DE5-4BCC-A807-C14CCB775C87Q36066469-094CE90A-9800-4D89-96B6-672690C6357F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Erwan Bezard
@ast
Erwan Bezard
@en
Erwan Bezard
@es
Erwan Bezard
@sl
type
label
Erwan Bezard
@ast
Erwan Bezard
@en
Erwan Bezard
@es
Erwan Bezard
@sl
altLabel
E Bezard
@en
prefLabel
Erwan Bezard
@ast
Erwan Bezard
@en
Erwan Bezard
@es
Erwan Bezard
@sl
P106
P21
P31
P4012
P496
0000-0002-0410-4638
P569
2000-01-01T00:00:00Z